# US 12,760,123 B2 · Bispecific antibodies binding HVEM and CD9

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,760,123 B2
- Document ID: US12760123B2
- Status: Granted
- Kind: B2
- Application number: 17/929,028
- Filed: 2020-02-13
- Published: 2023-06-22
- Granted: 2026-10-13
- Earliest claimed: 2020-02-13
- Assignees: Ucb Biopharma Srl
- Applicants: Ucb Biopharma Srl
- Inventors: David Alan Cook; Helen Margaret Finney; Stephen Edward Rapecki
- Web page: https://patentgrep.com/patent/US12760123B2

## CPC

- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to multispecific antibodies against a novel targets' combination of HVEM and CD9, and their use in the treatment of cancer and infectious diseases.

## Claims

### Claim 1

An antibody which comprises a first antigen-binding portion binding HVEM and a second antigen-binding portion binding CD9, wherein the first antigen-binding portion binding HVEM comprises a first heavy chain variable region and a first light chain variable region, wherein the second antigen-binding portion binding CD9 comprises a second heavy chain variable region and a second light chain variable region, and wherein:
a. the first heavy chain variable region comprises a CDR-H1 comprising SEQ ID NO: 3, a CDR-H2 comprising SEQ ID NO: 4 and a CDR-H3 comprising SEQ ID NO: 5; and
b. the first light chain variable region comprises a CDR-L1 comprising SEQ ID NO: 6, a CDR-L2 comprising SEQ ID NO: 7 and a CDR-L3 comprising SEQ ID NO: 8; and
c. the second heavy chain variable region comprises a CDR-H1 comprising SEQ ID NO: 9, a CDR-H2 comprising SEQ ID NO: 10 and a CDR-H3 comprising SEQ ID NO: 11; and
d. the second light chain variable region comprises a CDR-L1 comprising SEQ ID NO: 12, a CDR-L2 comprising SEQ ID NO: 13 and a CDR-L3 comprising SEQ ID NO: 14.

### Claim 2 (depends on 1)

The antibody according to claim 1, wherein each of the antigen-binding portions is a monoclonal antigen-binding portion.

### Claim 3 (depends on 1)

The antibody according to claim 1, wherein each of the antigen-binding portions is independently selected from a Fab, a Fab′, or a scFv.

### Claim 4 (depends on 1)

The antibody according to claim 1, wherein the antigen-binding portions are the antigen-binding portions of an IgG.

### Claim 5 (depends on 1)

The antibody according to claim 1 wherein the antibody is chimeric, human or humanised.

### Claim 6 (depends on 1)

The antibody according to claim 1, wherein the antibody comprises a heavy chain constant region selected from an IgG1, an IgG2, IgG3 or an IgG4 isotype, or a variant thereof.

### Claim 7 (depends on 1)

The antibody according to claim 1, wherein the antibody further comprises at least an additional antigen-binding portion.

### Claim 8 (depends on 7)

The antibody according to claim 7, wherein the additional antigen-binding portion is capable of increasing the half-life of the antibody.

### Claim 9 (depends on 8)

The antibody according to claim 8, wherein the additional antigen-binding portion binds albumin.

### Claim 10 (depends on 1)

The antibody according to claim 1, wherein the second antigen binding portion binds CD9 in CD9 loop 2.

### Claim 11 (depends on 1)

The antibody according to claim 1, wherein:
the first heavy chain variable region comprises SEQ ID NO: 15 and the first light chain variable region comprises SEQ ID NO: 17; and the second heavy chain variable region comprises SEQ ID NO: 19 and second light chain variable region comprises SEQ ID NO: 21; or
the first heavy chain variable region is encoded by a nucleotide sequence comprising SEQ ID NO: 16 and the first light chain variable region is encoded by a nucleotide sequence comprising SEQ ID NO: 18; and the second heavy chain variable region is encoded by a nucleotide sequence comprising SEQ ID NO: 20 and second light chain variable region is encoded by a nucleotide sequence comprising SEQ ID NO: 22.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the antibody according to claim 1 and one or more pharmaceutically acceptable excipients.